The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...

The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.

Fintel reports that on March 10, 2025, Scotiabank upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Sector ...

Fintel reports that on March 10, 2025, Jones Trading upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Hold ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...

We recently compiled a list of the 10 Best Emerging Technology Stocks to Buy Now. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against the other ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...